Table 1. Epidemiologic characteristics of FCCTX compared with Lynch syndrome and non-Amsterdam Criteria-1 colorectal cases in the Colon Cancer Family Registry.
| Characteristic, n (%) | FCCTX (n=173) | Lynch (n=303) | Non-AC1 (n=9,603) | FCCTX vs Lyncha ORb (95% CI) | FCCTX vs non-AC1a ORb (95% CI) | Lynch vs non-AC1a ORb (95% CI) |
|---|---|---|---|---|---|---|
|
Case characteristicsc | ||||||
| Age, mean (s.d.) | 53.3 (11.3) | 50.5 (11.4) | 56.3 (12.0) | 1.02 (1.00, 1.03) | 0.99 (0.98, 1.00) | 0.97 (0.96, 0.98) |
| Male gender | 76 (44%) | 149 (49%) | 4797 (50%) | 0.81 (0.56, 1.18) | 0.80 (0.59, 1.09) | 0.99 (0.79, 1.25) |
| BMI, mean (s.d.) |
27.5 (6.6) |
26.5 (5.8) |
27.2 (5.8) |
1.03 (0.10, 1.07) |
1.02 (0.99, 1.04) |
0.98 (0.96, 1.01) |
|
Smoking | ||||||
| Never | 85 (49%) | 148 (49%) | 4252 (45%) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Former | 74 (43%) | 106 (35%) | 4198 (44%) | 1.17 (0.78, 1.76) | 0.99 (0.72, 1.37) | 0.85 (0.65, 1.11) |
| Current |
13 (8%) |
49 (16%) |
1096 (11%) |
0.48 (0.24, 0.94) |
0.62 (0.35, 1.13) |
1.30 (0.93, 1.83) |
|
Co-morbidities (yes/no) (% yes) | ||||||
| Diabetes | 17/155 (9%) | 20/283 (7%) | 1154/8404 (12%) | 1.48 (0.74, 2.94) | 1.16 (0.69, 1.94) | 0.78 (0.49, 1.25) |
| Hyperlipidemia | 42/129 (24%) | 79/222 (26%) | 2995/6530 (31%) | 0.84 (0.53, 1.31) | 0.88 (0.61, 1.27) | 1.05 (0.80, 1.39) |
| Aspirin | 38/134 (22%) | 68/231 (22%) | 2771/6747 (29%) | 0.83 (0.52, 1.34) | 0.99 (0.68, 1.46) | 1.19 (0.89, 1.60) |
| Acetaminophen | 23/149 (13%) | 51/250 (17%) | 1469/8026 (15%) | 0.72 (0.42, 1.23) | 0.81 (0.52, 1.27) | 1.13 (0.83, 1.55) |
| NSAIDs | 31/141 (18%) | 53/249 (17%) | 1555/7910 (16%) | 1.01 (0.62, 1.66) | 1.16 (0.78, 1.73) | 1.14 (0.84, 1.56) |
| Laxatives | 39/133 (23%) | 60/242 (20%) | 2136/7375 (22%) | 1.04 (0.65, 1.65) | 1.04 (0.72, 1.51) | 1.01 (0.75, 1.36) |
| Multivitamin | 73/99 (42%) | 131/171 (43%) | 4829/4702 (50%) | 0.88 (0.60, 1.31) | 0.98 (0.71, 1.34) | 1.10 (0.86, 1.41) |
| Folic acid | 22/150 (13%) | 39/261 (13%) | 941/8528 (10%) | 1.03 (0.58, 1.84) | 1.13 (0.70, 1.80) | 1.09 (0.76, 1.57) |
| Calcium |
36/136 (21%) |
59/244 (19%) |
2507/7012 (26%) |
0.84 (0.51, 1.38) |
0.80 (0.54, 1.19) |
0.95 (0.70, 1.30) |
|
Female (yes/no) (% yes) | ||||||
| Oral hormonal contraceptives | 70/27 (72%) | 115/39 (75%) | 2783/1972 (58%) | 0.93 (0.50, 1.72) | 1.31 (0.81, 2.12) | 1.41 (0.95, 2.09) |
| PMH with uterus intact | 23/41 (36%) | 48/67 (41%) | 1041/1805 (36%) | 0.44 (0.05, 3.92) | 0.90 (0.12, 6.80) | 2.04 (0.76, 5.42) |
| PMH with hysterectomy | 6/12 (33%) | 12/26 (32%) | 314/471 (39%) | 0.68 (0.35, 1.34) | 1.19 (0.68, 2.09) | 1.76 (1.17, 2.64) |
Abbreviations: AC1=Amsterdam Criteria-1; BMI=body mass index; FCCTX=Familial Colorectal Cancer Type X; PMH=post-menopausal hormone use; s.d.=standard deviation.
a
All models are adjusted for age at diagnosis, sex, and study site.
b
OR per one unit increase in continuous variables (age at diagnosis and BMI). For binary variables, the reference group is those without the characteristic.
c
Age=age at diagnosis (years); BMI=BMI two years prior to diagnosis (kg m−2).